Biotechnology
Compare Stocks
4 / 10Stock Comparison
MPLT vs ACNB vs CZWI vs PTGX
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Banks - Regional
Biotechnology
MPLT vs ACNB vs CZWI vs PTGX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Banks - Regional | Banks - Regional | Biotechnology |
| Market Cap | $1.33B | $544M | $202M | $6.79B |
| Revenue (TTM) | $0.00 | $170M | $90M | $18M |
| Net Income (TTM) | $-103M | $37M | $14M | $-115M |
| Gross Margin | — | 73.7% | 54.7% | 100.0% |
| Operating Margin | — | 27.3% | 7.0% | -8.1% |
| Forward P/E | — | 9.6x | 11.3x | 25.7x |
| Total Debt | $7M | $329M | $52M | $10M |
| Cash & Equiv. | $38M | $21M | $119M | $128M |
MPLT vs ACNB vs CZWI vs PTGX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| ACNB Corporation (ACNB) | 100 | 209.5 | +109.5% |
| Citizens Community … (CZWI) | 100 | 280.0 | +180.0% |
| Protagonist Therape… (PTGX) | 100 | 618.1 | +518.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MPLT vs ACNB vs CZWI vs PTGX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MPLT plays a supporting role in this comparison — it may shine differently against other peers.
ACNB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 8 yrs, beta 0.68, yield 2.7%
- Rev growth 28.9%, EPS growth -3.5%
- PEG 0.87 vs CZWI's 2.23
- NIM 3.8% vs CZWI's 2.9%
CZWI is the clearest fit if your priority is defensive.
- Beta 0.45, yield 1.8%, current ratio 3015.31x
PTGX is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 8.0% 10Y total return vs ACNB's 179.5%
- Lower volatility, beta 0.23, Low D/E 1.7%, current ratio 12.71x
- Beta 0.23 vs ACNB's 0.68, lower leverage
- +141.1% vs ACNB's +22.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 28.9% NII/revenue growth vs PTGX's -89.4% | |
| Value | Lower P/E (9.6x vs 25.7x) | |
| Quality / Margins | 21.7% margin vs PTGX's -6.5% | |
| Stability / Safety | Beta 0.23 vs ACNB's 0.68, lower leverage | |
| Dividends | 2.7% yield, 8-year raise streak, vs CZWI's 1.8%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +141.1% vs ACNB's +22.7% | |
| Efficiency (ROA) | 1.1% ROA vs MPLT's -69.7%, ROIC 5.3% vs -153.7% |
MPLT vs ACNB vs CZWI vs PTGX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MPLT vs ACNB vs CZWI vs PTGX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACNB leads in 3 of 6 categories
PTGX leads 2 • MPLT leads 0 • CZWI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ACNB leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACNB and MPLT operate at a comparable scale, with $170M and $0 in trailing revenue. ACNB is the more profitable business, keeping 21.7% of every revenue dollar as net income compared to PTGX's -6.5%.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $170M | $90M | $18M |
| EBITDAEarnings before interest/tax | -$108M | $53M | $9M | -$141M |
| Net IncomeAfter-tax profit | -$103M | $37M | $14M | -$115M |
| Free Cash FlowCash after capex | -$113M | $51M | $11M | -$116M |
| Gross MarginGross profit ÷ Revenue | — | +73.7% | +54.7% | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | +27.3% | +7.0% | -8.1% |
| Net MarginNet income ÷ Revenue | — | +21.7% | +16.0% | -6.5% |
| FCF MarginFCF ÷ Revenue | — | +30.9% | +11.5% | -6.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +35.1% | +63.0% | +126.3% |
Valuation Metrics
Evenly matched — ACNB and CZWI each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 14.3x trailing earnings, CZWI trades at a 2% valuation discount to ACNB's 14.6x P/E. Adjusting for growth (PEG ratio), ACNB offers better value at 1.32x vs CZWI's 2.83x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.3B | $544M | $202M | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $853M | $134M | $6.7B |
| Trailing P/EPrice ÷ TTM EPS | -15.66x | 14.61x | 14.34x | -51.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.65x | 11.31x | 25.74x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.32x | 2.83x | — |
| EV / EBITDAEnterprise value multiple | — | 16.03x | 15.12x | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.20x | 2.24x | 147.52x |
| Price / BookPrice ÷ Book value/share | 10.53x | 1.29x | 1.08x | 10.92x |
| Price / FCFMarket cap ÷ FCF | — | 10.36x | 19.41x | 121.04x |
Profitability & Efficiency
ACNB leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ACNB delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-2 for MPLT. PTGX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACNB's 0.78x. On the Piotroski fundamental quality scale (0–9), CZWI scores 6/9 vs PTGX's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +9.2% | +7.8% | -17.8% |
| ROA (TTM)Return on assets | -69.7% | +1.1% | +0.8% | -16.5% |
| ROICReturn on invested capital | -153.7% | +5.3% | +2.0% | -21.8% |
| ROCEReturn on capital employed | -83.9% | +2.5% | +0.6% | -23.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.78x | 0.28x | 0.02x |
| Net DebtTotal debt minus cash | -$32M | $308M | -$67M | -$118M |
| Cash & Equiv.Liquid assets | $38M | $21M | $119M | $128M |
| Total DebtShort + long-term debt | $7M | $329M | $52M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | 1.16x | 0.16x | — |
Total Returns (Dividends Reinvested)
PTGX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTGX five years ago would be worth $34,641 today (with dividends reinvested), compared to $16,263 for MPLT. Over the past 12 months, PTGX leads with a +141.1% total return vs ACNB's +22.7%. The 3-year compound annual growth rate (CAGR) favors PTGX at 59.6% vs MPLT's 17.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +62.6% | +12.1% | +21.3% | +21.1% |
| 1-Year ReturnPast 12 months | +62.6% | +22.7% | +40.9% | +141.1% |
| 3-Year ReturnCumulative with dividends | +62.6% | +91.0% | +174.8% | +306.4% |
| 5-Year ReturnCumulative with dividends | +62.6% | +105.4% | +69.0% | +246.4% |
| 10-Year ReturnCumulative with dividends | +62.6% | +179.5% | +154.0% | +802.1% |
| CAGR (3Y)Annualised 3-year return | +17.6% | +24.1% | +40.1% | +59.6% |
Risk & Volatility
PTGX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PTGX is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than ACNB's 0.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PTGX currently trades 97.9% from its 52-week high vs MPLT's 88.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | — | 0.69x | 0.50x | 0.20x |
| 52-Week HighHighest price in past year | $33.28 | $53.93 | $22.62 | $107.84 |
| 52-Week LowLowest price in past year | $16.34 | $40.15 | $12.83 | $43.20 |
| % of 52W HighCurrent price vs 52-week peak | +88.0% | +97.5% | +92.5% | +97.9% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 57.2 | 57.9 | 54.8 |
| Avg Volume (50D)Average daily shares traded | 264K | 62K | 38K | 726K |
Analyst Outlook
ACNB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACNB as "Buy", CZWI as "Buy", PTGX as "Buy". Consensus price targets imply 15.4% upside for MPLT (target: $34) vs 9.3% for PTGX (target: $115). For income investors, ACNB offers the higher dividend yield at 2.66% vs CZWI's 1.77%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $33.80 | $58.00 | — | $115.40 |
| # AnalystsCovering analysts | — | 2 | 2 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% | +1.8% | — |
| Dividend StreakConsecutive years of raises | — | 8 | 7 | — |
| Dividend / ShareAnnual DPS | — | $1.40 | $0.37 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.1% | +3.1% | 0.0% |
ACNB leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PTGX leads in 2 (Total Returns, Risk & Volatility). 1 tied.
MPLT vs ACNB vs CZWI vs PTGX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MPLT or ACNB or CZWI or PTGX a better buy right now?
For growth investors, ACNB Corporation (ACNB) is the stronger pick with 28.
9% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Citizens Community Bancorp, Inc. (CZWI) offers the better valuation at 14. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate ACNB Corporation (ACNB) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MPLT or ACNB or CZWI or PTGX?
On trailing P/E, Citizens Community Bancorp, Inc.
(CZWI) is the cheapest at 14. 3x versus ACNB Corporation at 14. 6x. On forward P/E, ACNB Corporation is actually cheaper at 9. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ACNB Corporation wins at 0. 87x versus Citizens Community Bancorp, Inc. 's 2. 23x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MPLT or ACNB or CZWI or PTGX?
Over the past 5 years, Protagonist Therapeutics, Inc.
(PTGX) delivered a total return of +246. 4%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: PTGX returned +773. 3% versus MPLT's +59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MPLT or ACNB or CZWI or PTGX?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.
(PTGX) is the lower-risk stock at 0. 20β versus ACNB Corporation's 0. 69β — meaning ACNB is approximately 246% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 78% for ACNB Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MPLT or ACNB or CZWI or PTGX?
By revenue growth (latest reported year), ACNB Corporation (ACNB) is pulling ahead at 28.
9% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Citizens Community Bancorp, Inc. grew EPS 9. 0% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MPLT or ACNB or CZWI or PTGX?
ACNB Corporation (ACNB) is the more profitable company, earning 21.
7% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MPLT or ACNB or CZWI or PTGX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ACNB Corporation (ACNB) is the more undervalued stock at a PEG of 0. 87x versus Citizens Community Bancorp, Inc. 's 2. 23x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ACNB Corporation (ACNB) trades at 9. 6x forward P/E versus 25. 7x for Protagonist Therapeutics, Inc. — 16. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MPLT: 15. 4% to $33. 80.
08Which pays a better dividend — MPLT or ACNB or CZWI or PTGX?
In this comparison, ACNB (2.
7% yield), CZWI (1. 8% yield) pay a dividend. MPLT, PTGX do not pay a meaningful dividend and should not be held primarily for income.
09Is MPLT or ACNB or CZWI or PTGX better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc.
(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20), +773. 3% 10Y return). Both have compounded well over 10 years (PTGX: +773. 3%, MPLT: +59. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MPLT and ACNB and CZWI and PTGX?
These companies operate in different sectors (MPLT (Healthcare) and ACNB (Financial Services) and CZWI (Financial Services) and PTGX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MPLT is a small-cap quality compounder stock; ACNB is a small-cap high-growth stock; CZWI is a small-cap deep-value stock; PTGX is a small-cap quality compounder stock. ACNB, CZWI pay a dividend while MPLT, PTGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.